

Glycoengineered keratinocyte library reveals essential functions of specific glycans for all stages of HSV-1 infection

Ieva Bagdonaite^{1*}, Irina N Marinova¹, Asha M Rudjord-Levann¹, Emil MH Pallesen¹, Sarah King-Smith¹, Richard Karlsson¹, Troels B Rømer¹, Yen-Hsi Chen¹, Rebecca L Miller¹, Sigvard Olofsson², Rickard Nordén², Tomas Bergström², Sally Dabelsteen³ and Hans H Wandall^{1*}

¹ Copenhagen Center for Glycomics, Institute of Cellular and Molecular Medicine, University of Copenhagen, DK-2200 Copenhagen, Denmark

² Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, SE-41346 Gothenburg, Sweden

³ School of Dentistry, University of Copenhagen, DK-2200 Copenhagen, Denmark

Supplementary Information

Supplementary Table 1. Knock out indel sequencing and sgRNA/ZFN targeting sequences

Supplementary Table 2. CS disaccharide quantification in HaCaT WT

Supplementary Table 3. HS disaccharide quantification in HaCaT WT

Supplementary Table 4. Mutagenic primers

Supplementary Table 5. Oligonucleotide sequences for annealing and cloning the DNA template for gRNA into the LentiCRISPR-V2 plasmid

Supplementary Figure 1. N-glycoprofiling

Supplementary Figure 2. CORA O-glycoprofiling

Supplementary Figure 3. Flow cytometry supporting data

Supplementary Figure 4. Disaccharide analysis of HaCaT WT and *B4GALT7* KO cells

Supplementary Figure 5. Sequencing of DNA constructs

Supplementary Figure 6. Section panels of HSV-1-infected glycoengineered organotypic skin

Supplementary Table 1. Knock out indel sequencing and sgRNA/ZFN targeting sequences

Gene	Clone	Sequence ¹	gRNA/ZFN (5'-3')	Indel	First affected a.a.
<u>N-Glycan</u>					
MGAT1 KO	REF	GATtcgcctggcccaagacgccc <u>AGG</u>	TCGCCTGGCCCAAGACGCCG		
	1E7_A1	GATtcgcctggcccaag----cgCGG		-4	60
	1E7_A2	GATtcgcctggcccaagacg-cgAGG		-1	61
MGAT4A KO	REF	aatgagatgaggctccgcaa <u>TGGAAC</u>	AATGAGATGAGGCTCCGCAA		
	3C10_A1	aatgagatgaggctcc--aaTGGAAC		-2	4
	3C10_A2	aatgagatgaggctccgca-TGGAAC		-1	5
MGAT4B KO	REF	TTG...GCAGgagagcctcaagc-gctcca <u>AGGAGCTCAACCTGGTGCTGG</u>	GGAGAGCCTCAAGCGCTCCA		
	3F8_A1	TTG...GCAGgagagcctcaagcTgctccaAGGAGCTCAACCTGGTGCTGG		+1	60
	3F8_A2	TTG...-----TGG		-96	36
MGAT5+4B KO	2B5 A1 (in MGAT5 KO 1F12)	TTG...GCAGga-----GAGCTCAACCTGGTGCTGG		-19	56
MGAT5 KO	REF	GGGCC <u>A</u> taC-----gctggagtcatgacagcTTAT	GCTGTCATGACTCCAGCGTA		
	1F12_A1	GGGCCAtacA-----gctggagtcatgacagcTTAT		+1	74
	1F12_A2	GGGCCACATGACATAGgctggagtcatgacagcTTAT		+7	73
<u>O-GalNAc</u>					
C1GALT1C1 KO ²	REF	ATCACCCCAACCAGGTAGTagaaggctGTTGTT <u>CAGATAT</u>	AGAAGGCT (ZFN cut site)		
	D5_A1	ATCACCCCAACCAGGTA-----GTTGTT <u>CAGATAT</u>		-10	267

¹ Sequences are shown in the orientation of the gene, with sgRNA recognition sequences (direct or complementary)/ZFN cut sites in lower case and PAM sequences underlined

² Radhakrishnan *et al.*, 2014 (DOI: 10.1073/pnas.1406619111)

<i>C1GALT1</i> KO	REF	GCCC <u>A</u> gcgttgtaacaaagtgttgtTTATGAGTTCAGAA	ACAACACTTTGTTACAACGC		
	2E5_A1	GCCCAG--TTGTAACAAAAGTGTGTTTATGAGTTCAGAA		-2	114
	2E5_A2	GCCCAGCG-----TGTGTTTATGAGTTCAGAA		-11	115
<i>GCNT1</i> KO	REF	AATC <u>ACC</u> TtctccgttttaaggattcatCAA	ATGAATCCTTAAAACGGAGA		
	2E7_A1	AAT-----ttaaggattcatCAA		-13	27
	2E7_A2	AATCACCTtc--cgttAATGgattcatCAA		-2	30
<i>ST3GAL1</i> KO	REF	TGGT <u>GCC</u> Cttc-aagaccatcgacttgaGTGGG	TCCAAGTCGATGGTCTTGAA		
	2B2_A1	TGGT <u>GCC</u> CttcAaagaccatcgacttgaGTGGG		+1	210
<u>GAG</u> <i>B4GALT7</i> KO	REF	TGCACGACGTtgacctgctccctctcaa-cg <u>AGG</u> AGCTGGAC	TGACCTGCTCCCTCTCAACG		
	3D9_A1	TGCACGACGTtgacctgctccctctcaaAcgAGGAGCTGGAC		+1	170
	3D9_A2	TGCACGACGTtgacctgctccctctc-----AC		-13	170
<u>GSL</u> <i>B4GALT5</i> KO	REF	AGCCTTCTGATTGCat-----gccTCGGTGGGAAG	ATGCC (ZFN cut site)		
	D11_A1	AGCCTTCTGATTGCATGTAGAATTCCCTAGCCTCGGTGGGAAG		+13	160
<i>ST3GAL5</i> KO	REF	GTTat ^t tgagcacaggtata-gcg <u>TGG</u> ACTTAC	ATTTGAGCACAGGTATAGCG		
	1C5_A1	GTTat ^t tgagcacaggtataCgcgTGGACTTAC		+1	138
	1C5_A2	GTTat ^t tgagcGTAA-----TGGACTTAC		-8	135

Supplementary Table 2. CS disaccharide quantification in HaCaT WT.

Standards						HaCaT WT			
Name	MW	Abbreviation	Elution time, min	Fluorescence signal intensity	Picomoles/fluoresc. unit	Fluorescence signal intensity	Picomoles	Molar %	µg
UA2S-GalNAc4S	605.388	D2A4	24.060	2279265	0.000008775	1102217	9.6717	1.70	0.006
UA-GalNAc4S6S	605.388	D0A10	26.241	2525125	0.000007920	8385507	66.4166	11.70	0.040
UA2S-GalNAc6S	605.388	D2A6	26.754	3868465	0.000005170	1732606	8.9576	1.58	0.005
UA-GalNAc4S	503.344	D0A4	29.134	1997232	0.000010014	32580632	326.2579	57.46	0.164
UA2S-GalNAc	503.344	D2A0	29.412	5229740	0.000003824	0	0.0000	0.00	0.000
UA-GalNAc6S	503.344	D0A6	30.810	2541577	0.000007869	18234958	143.4933	25.27	0.072
UA-GalNAc	401.300	D0A0	33.046	2631878	0.000007599	1706858	12.9706	2.28	0.005

Supplementary Table 3. HS disaccharide quantification in HaCaT WT.

Standards						HaCaT WT			
Name	MW	Abbreviation	Elution time, min	Fluorescence signal intensity	Picomoles/fluoresc. unit	Fluorescence signal intensity	Picomoles	Molar %	µg
UA-GlcNAc	401.300	IV-A	52.718	1509711	0.00001325	12516037	165.8071	15.29	0.067
UA2S-GlcNAc	503.344	III-A	47.949	1930891	0.00001036	2358398	24.4281	2.25	0.012
UA-GlcNAc6S	503.344	II-A	40.829	1923938	0.00001040	ND*	0.0000	0.00	0.000
UA2S-GlcNAc6S	605.388	I-A	37.379	1599135	0.00001251	0	0.0000	0.00	0.000
UA-GlcNH ₂	337.281	IV-H	37.996	2105780	0.00000950	0	0.0000	0.00	0.000
UA2S-GlcNH ₂	461.307	III-H	35.017	1596156	0.00001253	59749	0.7487	0.07	0.000
UA-GlcNH ₂ 6S	461.307	II-H	30.481	1591894	0.00001256	0	0.0000	0.00	0.000
UA2S-GlcNH ₂ 6S	564.359	I-H	28.037	1643712	0.00001217	0	0.0000	0.00	0.000
UA-GlcNS	461.307	IV-S	25.568	1710782	0.00001169	32235845	376.8551	34.75	0.174
UA2S-GlcNS	563.351	III-S	20.983	1578920	0.00001267	22187109	281.0416	25.91	0.158
UA-GlcNS6S	563.351	II-S	16.089	1254200	0.00001595	4449247	70.9496	6.54	0.040
UA2S-GlcNS6S	665.395	I-S	13.790	1904574	0.00001050	15293468	160.5973	14.81	0.107
UA-GlcNS3S	563.351	VIII-S	14.708	1645590	0.00001215	64732	0.7867	0.07	0.000
UA2S-GlcNS3S	665.395	VII-S	14.213	1936850	0.00001033	ND*	0.0000	0.00	0.000
UA-GlcNS3S6S	665.395	VI-S	10.962	1452743	0.00001377	25165	0.3464	0.03	0.000
UA2S-GlcNS3S6S	767.439	V-S	10.459	1428129	0.00001400	209107	2.9284	0.27	0.002

*ND – not quantified due to overlap with other peaks


Supplementary Table 4. Sequences of mutagenic primers. Altered nucleotides are shown in red.

Name	5' to 3'	Length
gB_T169A	GTACTACAAAGACGTCGCCGTTTCGCAGGTGTG	33
gB_T267A	CCACCGGTACGGGGCGACGGTAAACTG	27
gB_T268A	ACCGGTACGGGACGCGGTAAACTGCATC	29
gB_T267A_T268A	TCCACCGGTACGGGGCGGCGGTAAACTGCATC	32
gB_T690A	CCTGGAGGTGTACGCCCGCCACGAGATC	28
gB_T703A	CCTGCTGGACTACCGGAGGTCCAGCG	27
gD_S33A	CCTTGCGGATGCCGCTCTCAAGATGGCC	29
gD_T255A	CGAGAACCAGCGCGCCGTCGCCGTATA	27
gD_S260A	ACCGTCGCCGTATACGCCCTTGAAGATCGCCGG	32
gD_T255A_S260A	CGAGAACCAGCGCGCCGTCGCCGTATACGCCCTTGAAGATCGCCGG	45



Supplementary Table 5. Oligonucleotide sequences for annealing and cloning the DNA template for gRNA into the LentiCRISPR-V2 plasmid.

Target gene	gRNA targeting sequence (5' to 3')	5' oligonucleotide sequence (5' to 3')	3' oligonucleotide sequence (5' to 3')
<i>MGAT1</i>	TCGCCTGGCCCAAGACGCCG	CACCGTCGCCTGGCCCAAGACGCCG	AAACCGCGTCTTGGGCCAGGCGAC
<i>MGAT4A</i>	AATGAGATGAGGCTCCGCAA	CACCGAATGAGATGAGGCTCCGCAA	AAACTTGGGAGCCTCATCTCATTC
<i>MGAT4B</i>	GGAGAGCCTCAAGCGCTCCA	CACCGGGAGAGCCTCAAGCGCTCCA	AAACTGGAGCGCTTGAGGCTCTCCC
<i>MGAT5</i>	GCTGTCATGACTCCAGCGTA	CACCGGCTGTCATGACTCCAGCGTA	AAACTACGCTGGAGTCATGACAGCC
<i>C1GALT1</i>	ACAACACTTTGTTACAACGC	CACCGACAACACTTTGTTACAACGC	AAACGCGTTGTAACAAAGTGTGTC
<i>GCNT1</i>	ATGAATCCTTAAAACGGAGA	CACCGATGAATCCTTAAAACGGAGA	AAACTCTCGTTTTTAAGGATTCATC
<i>ST3GAL1</i>	TCCAAGTCGATGGTCTTGAA	CACCGTCCAAGTCGATGGTCTTGAA	AAACTTCAAGACCATCGACTTGGAC
<i>B4GALT7</i>	TGACCTGCTCCCTCTCAACG	CACCGTGACCTGCTCCCTCTCAACG	AAACCGTTGAGAGGGAGCAGGTCAC
<i>ST3GAL5</i>	ATTTGAGCACAGGTATAGCG	CACCGATTTGAGCACAGGTATAGCG	AAACCGCTATACCTGTGCTCAAATC



Supplementary Figure 1. N-glycoprofiling




MGAT5 KO





MGAT4B/5 KO



Supplementary Figure 2. CORA O-glycoprofilng





Related to Fig. 2i

Related to Supplementary Fig. 3a and 3b

Related to Supplementary Fig. 3b

Related to Supplementary Fig. 3c

Related to Fig. 2h

Supplementary Figure 3. Flow cytometry supporting data. a Nectin 1 cell surface expression in CHO-Nectin 1 and parental CHO cell line. **b** HVEM cell surface expression in CHO-HVEM and parental CHO cell line. **c** Nectin 1 and HVEM cell surface expression in HEK293 cells. Background corrected median fluorescence intensity from two independent experiments is shown. **d** Gating strategies for various cell lines used for flow cytometry.

Supplementary Figure 5. Sequencing of DNA constructs. Multiple sequence alignment for the DNA regions corresponding to the positions of introduced single amino acid mutations in HSV-1 gB and gD expression constructs. Asterisks indicate identical nucleotides.

```

gB Tyr165-Val173      TyrLysAspValThrValSerGlnVal
                      Y K D V T V S Q V
gB_WT                 TACAAAGACGTCACCGTTTCGCAGGTG 27
gB_T169A              TACAAAGACGTCGCCGTTTCGCAGGTG 27
gB_T267A              TACAAAGACGTCACCGTTTCGCAGGTG 27
gB_T268A              TACAAAGACGTCACCGTTTCGCAGGTG 27
gB_T267A_T268A       TACAAAGACGTCACCGTTTCGCAGGTG 27
gB_T690A              TACAAAGACGTCACCGTTTCGCAGGTG 27
gB_T703A              TACAAAGACGTCACCGTTTCGCAGGTG 27
gB_T690A_T703A       TACAAAGACGTCACCGTTTCGCAGGTG 27
gB_T169A_T267A_T268A TACAAAGACGTCGCCGTTTCGCAGGTG 27
                      *****

gB His263-Ile272     HisArgTyrGlyThrThrValAsnCysIle
                      H R Y G T T V N C I
gB_WT                 CACCGGTACGGGACGACGTAACACTGCATC 30
gB_T169A              CACCGGTACGGGACGACGTAACACTGCATC 30
gB_T267A              CACCGGTACGGGGCGACGTAACACTGCATC 30
gB_T268A              CACCGGTACGGGACGCGGTAACACTGCATC 30
gB_T267A_T268A       CACCGGTACGGGGCGCGGTAACACTGCATC 30
gB_T690A              CACCGGTACGGGACGACGTAACACTGCATC 30
gB_T703A              CACCGGTACGGGACGACGTAACACTGCATC 30
gB_T690A_T703A       CACCGGTACGGGACGACGTAACACTGCATC 30
gB_T169A_T267A_T268A CACCGGTACGGGGCGCGGTAACACTGCATC 30
                      *****


gB Glu687-Gln706    GluValTyrThrArgHisGluIleLysAspSerGlyLeuLeuAspTyrThrGluValGln
                      E V Y T R H E I K D S G L L D Y T E V Q
gB_WT                 GAGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAG 60
gB_T169A              GAGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAG 60
gB_T267A              GAGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAG 60
gB_T268A              GAGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAG 60
gB_T267A_T268A       GAGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAG 60
gB_T690A              GAGGTGTACGCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAG 60
gB_T703A              GAGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACGCCGAGGTCCAG 60
gB_T690A_T703A       GAGGTGTACGCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACGCCGAGGTCCAG 60
gB_T169A_T267A_T268A GAGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAG 60
                      *****


gD Leu29-Ala37      LeuAlaAspAlaSerLeuLysMetAla
                      L A D A S L K M A
gD_WT                 TTGGCGGATGCCTCTCTCAAGATGGCC 27
gD_S33A               TTGGCGGATGCCTCTCTCAAGATGGCC 27
gD_T255A              TTGGCGGATGCCTCTCTCAAGATGGCC 27
gD_S260A              TTGGCGGATGCCTCTCTCAAGATGGCC 27
gD_T255A_S260A       TTGGCGGATGCCTCTCTCAAGATGGCC 27
gD_S33A_T255A_S260A TTGGCGGATGCCTCTCTCAAGATGGCC 27
                      *****


gD Glu251-Ala264    GluAsnGlnArgThrValAlaValTyrSerLeuLysIleAla
                      E N Q R T V A V Y S L K I A
gD_WT                 GAGAACCAGCGCACCGTTCGCGGTATACAGCTTGAAGATCGCC 42
gD_S33A               GAGAACCAGCGCACCGTTCGCGGTATACAGCTTGAAGATCGCC 42
gD_T255A              GAGAACCAGCGCGCCGTCGCGGTATACAGCTTGAAGATCGCC 42
gD_S260A              GAGAACCAGCGCACCGTTCGCGGTATACGCCCTTGAAGATCGCC 42
gD_T255A_S260A       GAGAACCAGCGCGCCGTCGCGGTATACGCCCTTGAAGATCGCC 42
gD_S33A_T255A_S260A GAGAACCAGCGCGCCGTCGCGGTATACGCCCTTGAAGATCGCC 42
                      *****

```



Supplementary Figure 6. Section panels of HSV-1-infected glycoengineered organotypic skin. 36 hours post-infection the tissues were fixed in formalin and two independent series of 10 consecutive sections with 30 μm intervals were stained with goat anti-HSV-1 FITC pAb followed by imaging with a fluorescence-equipped slide scanner.









X010780 *MGAT1* KO 1E7 + HSV-1 36 h section series 2




X01078P *MGAT4A* KO 3C10 + HSV-1 36 h section series 1




X01078P *MGAT4A* KO 3C10 + HSV-1 36 h section series 2




X01105L *MGAT4B* KO 3F8 + HSV-1 36 h section series 1





X01078Q_MGAT5 KO 1F12 + HSV-1 36 h section series 1



1

2

3

4

5

6

7


8

9


10

200 μm


X01078Q *MGAT5* KO 1F12 + HSV-1 36 h section series 2




X01105R *MGAT5+4B* KO 2B5 + HSV-1 36 h section series 1




X01105R *MGAT5+4B* KO 2B5 + HSV-1 36 h section series 2





X01078N *C1GALT1C1* KO D5 + HSV-1 36 h section series 1




X01078N C1GALTI1C1 KO D5 + HSV-1 36 h section series 2









X01105Q GCNT1 KO 2E7 + HSV-1 36 h section series 1





X01105Q GCNT1 KO 2E7 + HSV-1 36 h section series 2



200 μm







1

2

3

4

5

6

7

8

9


10


200 μm


X01105H B4GALT7 KO 3D9 + HSV-1 36 h section series 2

1 2 3 4 5 6 7 8 9 10


200 μ m







X01105P *ST3GAL5* KO 1C5 + HSV-1 36 h section series 1



X01105P *ST3GAL5* KO 1C5 + HSV-1 36 h section series 2

